Currently available therapies are too burdensome. Intrommune Therapeutics is developing easy-to-use oral products containing food proteins, making allergen exposure as easy as brushing your teeth.
About Us
With over 33 million Americans suffering from food allergies, Intrommune is focused on developing a safe, disease-modifying treatment with long-term efficacy through our oral mucosal immunotherapy (OMIT) platform that can help provide a much-needed solution.
Our novel drug delivery platform provides an elegant solution for food allergies by embedding therapeutic agents in a fully functional toothpaste that can be conveniently administered as daily treatment at the same time patients brush their teeth.